University of Wolverhampton
Collection All
Listed communities

Wolverhampton Intellectual Repository and E-Theses > School of Health & Wellbeing > Centre for Health and Social Care Improvement > Angiogenesis in chronically ischaemic human heart following percutaneous myocardial revascularisation.

Please use this identifier to cite or link to this item:     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!

Title: Angiogenesis in chronically ischaemic human heart following percutaneous myocardial revascularisation.
Authors: Cotton, James M.
Thomas, M.R.
Dunmore, Simon J.
Salisbury, J.
Shah, Ajay M.
Brindle, N.P.J.
Citation: Heart, 87(3): 281-283
Publisher: BMJ Journals
Journal: Heart
Issue Date: 2002
PubMed ID: 11847177
Additional Links:
Abstract: Patients with intractable angina and severe diffuse coronary artery disease not amenable to conventional revascularisation therapy have relatively few treatment options. A number of studies suggest myocardial laser revascularisation is of clinical benefit in such patients.1, 2 Percutaneous myocardial revascularisation (PMR) involves the use of an intravascular catheter, positioned within the left ventricular cavity under fluoroscopic guidance, to deliver controlled bursts of holmium:YAG laser energy. PMR results in the formation of small channels (~1.75 mm diameter) that extend from the endocardial surface partly into the myocardial wall. Many uncontrolled studies suggest that PMR provides symptomatic relief, although the first randomised controlled trial demonstrated no benefit over a sham procedure.3 It has been suggested that PMR induces angiogenesis, although many other mechanisms of action have been suggested. To determine whether PMR has any effects on angiogenesis in the human ischaemic myocardium we have undertaken a detailed histological and immunohistochemical examination of the hearts of two patients who died eight weeks and 52 weeks after apparently symptomatically successful PMR therapy. In this first detailed study of human myocardium subjected to percutaneous myocardial laser revascularisation, we report evidence of sustained myocardial neovascularisation in treated areas and of the presence of vascular endothelial growth factor (VEGF). Unexpectedly, most of the neovessels are abnormal and immature, lacking a smooth muscle coat. Furthermore, neovessels are largely confined to scar tissue. Both the above factors are likely to limit the extent to which angiogenesis following PMR could improve perfusion. In a broader context, our findings that, once formed, immature and abnormal neovessels are sustained long term in human myocardium, may be relevant to the general design of strategies for therapeutic angiogenesis in patients—for example, the direct application of angiogenic factors (or genes).
Type: Article
Language: en
Keywords: Angiogenesis
Percutaneous Myocardial Revascularisation
Vascular Endothelial Growth Factors
MeSH: Actins
Chronic Disease
Coronary Vessels
Endothelial Growth Factors
Heart Catheterization
Muscle, Smooth, Vascular
Myocardial Ischemia
Myocardial Revascularization
Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
ISSN: 1468-201X
Appears in Collections: Centre for Health and Social Care Improvement

Files in This Item:

There are no files associated with this item.

Related articles on PubMed
Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT).
Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A, Vanninen E, Mussalo H, Kauppila E, Simula S, Närvänen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Ylä-Herttuala S
2003 Jun 3
Clinical and experimental evidence of prostaglandin E1-induced angiogenesis in the myocardium of patients with ischemic heart disease.
Mehrabi MR, Serbecic N, Tamaddon F, Kaun C, Huber K, Pacher R, Wild T, Mall G, Wojta J, Glogar HD
2002 Nov
See all 104 articles

All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.


Fairtrade - Guarantees a better deal for Third World Producers

University of Wolverhampton, Wulfruna Street, Wolverhampton, WV1 1LY

Course enquiries: 0800 953 3222, General enquiries: 01902 321000,
Email: | Freedom of Information | Disclaimer and copyright | Website feedback | The University as a charity

OR Logo Powered by Open Repository | Cookies